LICENSE AGREEMENT between 4D Molecular Therapeutics, Inc. and ASTELLAS GENE THERAPIES, INC. Dated as of July 5, 2023License Agreement • November 9th, 2023 • 4D Molecular Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledNovember 9th, 2023 Company Industry JurisdictionThis License Agreement (the “Agreement”) is made and entered into effective as of July 5, 2023 (the “Effective Date”) by and between 4D Molecular Therapeutics, Inc., a Delaware corporation (“Licensor”), and Astellas Gene Therapies, Inc. (f/k/a Audentes Therapeutics, Inc.), a Delaware corporation (“AGT”). Licensor and AGT are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”